Adalimumab use in patients with psoriasis and hepatitis B: a case series

Abstract

Tumor necrosis factor (TNF) inhibitors neutralize the biologic activity of TNF-alpha, a key cytokine involved in both the pathogenesis of psoriasis and host immune response in suppressing microbial proliferation.¹ It is well known that chronic hepatitis B virus (HBV) carriers are at high risk of HBV reactivation when using immunosuppressive medications, chemotherapy, and TNF inhibitors.^2-4 However, HBV reactivation in patients with resolved HBV infection using TNF inhibitors is exceedingly rare, and to our knowledge has not been reported in the psoriasis literature.

This article is protected by copyright. All rights reserved.

http://ift.tt/2taWtTu